Ana Paula B. Vintém

Ana Paula B. Vintém

Auto-generated profile, based on publicly available information

Ana Paula B. Vintém

Sanofi 1 NANOBODY Research Platform Ghent, Belgium

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PMPaolo Meoni
Paolo Meoni
AVAna Paula B. Vintém
Ana Paula B. Vintém
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
JJJasper Jacobs
Jasper Jacobs
ETEvelyn De Tavernier
Evelyn De Tavernier
MBMarie-Ange Buyse
Marie-Ange Buyse
T-cell engager (TCE) immunotherapy has demonstrated significant clinical activity in multiple cancers by inducing coengagement of T cells and tumor cells, resulting in T-cell activation and T cell–dependent cellular cytotoxicity (TDCC) against tumor cells. Current-generation TCEs are predominantly composed of antibody-based binding domains targeting the cluster of differentiation 3e molecule of the T-cell antigen receptor (TCR)–cluster of differentiation 3 complex on T cells and a tumor-associated antigen on tumor cells. However, limitations of this approach include cytokine release syndrome and a limited therapeutic window. In this study, we report the generation and preclinical evaluation of SAR444200, the first NANOBODY-based TCE clinical candidate binding to TCRαβ and glypican-3 (GPC3) to coengage T cells and GPC3+ tumor cells, causing TDCC. SAR444200 bound with nanomolar to picomolar affinity to TCRαβ and GPC3, respectively, and induced in vitro TDCC against multiple human tumor cell lines with differential GPC3 expression with picomolar potency. In vivo analysis using human cancer cell line–derived xenografts (HuH-7 and HepG2) in immunodeficient mice showed complete tumor regression at doses starting from 0.7 mg/kg. In exploratory non-human primate studies, intravenous administration of SAR444200 was well tolerated up to 8 mg/kg and exhibited greater than dose-proportional clearances and dose-proportional maximum concentrations across the tested dose range. The highly potent and efficacious activity of SAR444200 in diverse models of GPC3+ tumors and the extremely wide tolerated dose range merit further development of this compound. Furthermore, NANOBODY-based TCEs developed using an anti-TCRαβ moiety may have specific advantages for the development of TCEs.

8 January 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
ETEvelyn De Tavernier
Evelyn De Tavernier
PKPeter S. Kim
Peter S. Kim
EBEduardo Bruch
Eduardo Bruch
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
LTLien Timmerman
Lien Timmerman
AVAna Paula B. Vintém
Ana Paula B. Vintém
The standard of care for patients with HER2-positive cancers is well established, but a significant unmet need exists for patients with HER2-low tumors, who do not meet the eligibility criteria for trastuzumab, and for patients with HER2-positive tumors, who are refractory to trastuzumab treatment. Therefore, in this study, we developed a NANOBODY domain–based HER2-targeting, T-cell receptor αβ–based T-cell engager (TCE) molecule—TPP-45142; it recognizes a HER2 epitope distinct from that recognized by trastuzumab and pertuzumab and redirects T cells to kill HER2-low cancers such as breast, gastric, and gastroesophageal junction adenocarcinoma cancers. TPP-45142 mediated potent T cell–dependent cytotoxicity against HER2-low cancer cell lines in vitro and inhibited in vivo tumor growth of HER2-low breast cancer xenografts. TPP-45142 was highly selective toward tumor cells expressing low HER2 levels than toward normal cardiac cells and exhibited a favorable therapeutic index as per a cytokine release assay. Thus, TPP-45142, with an improved safety profile, is a promising next-generation TCE for treating challenging HER2-low cancers.

2 March 2026
Verified
Other
Open access
PDF file
PMPaolo Meoni
Paolo Meoni
AVAna Paula B. Vintém
Ana Paula B. Vintém
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
JJJasper Jacobs
Jasper Jacobs
ETEvelyn De Tavernier
Evelyn De Tavernier
MBMarie-Ange Buyse
Marie-Ange Buyse
SPR-based single cycle kinetics analysis of SAR444200 to recombinant soluble cynomolgus monkey GPC3, three independent experiments

2 March 2026
Verified
Other
Open access
PMPaolo Meoni
Paolo Meoni
AVAna Paula B. Vintém
Ana Paula B. Vintém
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
JJJasper Jacobs
Jasper Jacobs
ETEvelyn De Tavernier
Evelyn De Tavernier
MBMarie-Ange Buyse
Marie-Ange Buyse
T-cell engager (TCE) immunotherapy has demonstrated significant clinical activity in multiple cancers by inducing coengagement of T cells and tumor cells, resulting in T-cell activation and T cell–dependent cellular cytotoxicity (TDCC) against tumor cells. Current-generation TCEs are predominantly composed of antibody-based binding domains targeting the cluster of differentiation 3e molecule of the T-cell antigen receptor (TCR)–cluster of differentiation 3 complex on T cells and a tumor-associated antigen on tumor cells. However, limitations of this approach include cytokine release syndrome and a limited therapeutic window. In this study, we report the generation and preclinical evaluation of SAR444200, the first NANOBODY-based TCE clinical candidate binding to TCRαβ and glypican-3 (GPC3) to coengage T cells and GPC3+ tumor cells, causing TDCC. SAR444200 bound with nanomolar to picomolar affinity to TCRαβ and GPC3, respectively, and induced in vitro TDCC against multiple human tumor cell lines with differential GPC3 expression with picomolar potency. In vivo analysis using human cancer cell line–derived xenografts (HuH-7 and HepG2) in immunodeficient mice showed complete tumor regression at doses starting from 0.7 mg/kg. In exploratory non-human primate studies, intravenous administration of SAR444200 was well tolerated up to 8 mg/kg and exhibited greater than dose-proportional clearances and dose-proportional maximum concentrations across the tested dose range. The highly potent and efficacious activity of SAR444200 in diverse models of GPC3+ tumors and the extremely wide tolerated dose range merit further development of this compound. Furthermore, NANOBODY-based TCEs developed using an anti-TCRαβ moiety may have specific advantages for the development of TCEs.

2 March 2026
Verified
Other
Open access
PDF file
PMPaolo Meoni
Paolo Meoni
AVAna Paula B. Vintém
Ana Paula B. Vintém
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
JJJasper Jacobs
Jasper Jacobs
ETEvelyn De Tavernier
Evelyn De Tavernier
MBMarie-Ange Buyse
Marie-Ange Buyse
Flow cytometry binding curves and respective EC50 of SAR444200 for human and cyno T cells, HuH-7, and CHO expressing cyno GPC-3

2 March 2026
Verified
Other
Open access
PDF file
PMPaolo Meoni
Paolo Meoni
AVAna Paula B. Vintém
Ana Paula B. Vintém
VCVirna F. Cortez-Retamozo
Virna F. Cortez-Retamozo
JJJasper Jacobs
Jasper Jacobs
ETEvelyn De Tavernier
Evelyn De Tavernier
MBMarie-Ange Buyse
Marie-Ange Buyse
SPR-based single cycle kinetics analysis of SAR444200 to human SA, three independent experiments